Improving Ebola virus disease outbreak control through targeted post-exposure prophylaxis

Area of Science:

• Virology
• Infectious Diseases
• Public Health

Background:

• Ebola virus disease (EVD) has a high mortality rate, exceeding 50% of infected individuals.
• Transmission occurs through close human contact, allowing for risk stratification based on exposure type.
• Post-exposure prophylaxis (PEP) options, including vaccines, antivirals, and monoclonal antibodies, have varying benefits and limitations.

Purpose of the Study:

• To discuss the benefits and limitations of different Ebola virus disease (EVD) post-exposure prophylaxis (PEP) candidates.
• To highlight the potential of monoclonal antibodies as a targeted PEP strategy for high-risk individuals.
• To explore the integration of monoclonal antibodies and vaccines for comprehensive EVD protection.

Main Methods:

• Review of existing literature on Ebola virus disease (EVD) and post-exposure prophylaxis (PEP) strategies.
• Discussion of the mechanisms of action, benefits, and limitations of monoclonal antibodies, vaccines, and antivirals.
• Analysis of ongoing clinical research for refining PEP approaches.

Main Results:

• Approved monoclonal antibodies have demonstrated efficacy in reducing mortality in EVD patients.
• Monoclonal antibodies offer rapid, virus-specific targeting, making them suitable for high-risk contacts.
• Strategic integration of monoclonal antibodies and vaccines can provide both immediate and sustained protection.

Conclusions:

• Monoclonal antibodies represent a promising targeted PEP for high-risk individuals exposed to Ebola virus.
• Combining monoclonal antibodies with vaccines could offer a dual approach for immediate and long-term EVD prevention.
• Effective PEP strategies have the potential to significantly reduce mortality and control outbreaks of viral hemorrhagic fevers.